Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Alnylam Focuses On Pipeline Development Amid Competition

By Zacks Investment ResearchStock MarketsSep 18, 2019 11:02PM ET
www.investing.com/analysis/alnylam-focuses-on-pipeline-development-amid-competition-200466249
Alnylam Focuses On Pipeline Development Amid Competition
By Zacks Investment Research   |  Sep 18, 2019 11:02PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

We issued an updated report on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) on Sep 18.

The company’s only approved drug Onpattro’s (patisiran) uptake has been strong since its launch. In August 2018, the FDA approved Onpattro lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The drug is the first and only FDA-approved treatment for this indication. It should drive revenues for the company as it will be an important treatment option for people suffering from this often fatal disease.

In September 2019, Alnylam announced the initiation of a study of Onpattro to expand the label of the drug. The company initiated a phase III APOLLO-B study on Onpattro for the treatment of ATTR amyloidosis with cardiomyopathy. The initiation of APOLLO-B represents a significant milestone for the company to explore the full potential of Onpattro for patients living with all types of ATTR amyloidosis.

Shares of the company have gained 17.2% year to date against the industry’s decline of 1.1%.

The company is also evaluating several other candidates.

The company advanced givosiran, an investigational RNAi therapeutic in development for the treatment of acute hepatic porphyria (AHP). In June, Alnylam completed the rolling submission of a new drug application (NDA) to the FDA for the same. In August, the FDA accepted the company’s NDA for givosiran and granted a Priority Review for the same. The agency has set an action date of Feb 4, 2020, and indicated that it is not currently planning an advisory committee meeting as part of the NDA review. Givosiran is also under regulatory review in Europe.

Alnylam is also advancing lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type I (PH1). It continues enrollment in ILLUMINATE-A, a global phase III pivotal study on lumasiran in children and adult PH1 patients with preserved renal function. The company expects to report top-line results from the study later this year, and if positive, will file for global regulatory approvals in early 2020.

The company is also evaluating inclisiran (formerly known as PCSK9si or ALN-PCSsc), an investigational RNAi therapeutic, in phase II ORION studies for hypercholesterolemia. The company’s partner, The Medicines Company (NASDAQ:MDCO) , reported new results for the drug in developing the treatment for hypercholesterolemia. The company intends to file an NDA later this year.

The successful development and subsequent approval of these candidates will be a huge boost for the company.

Alnylam has entered several collaboration deals for the development and commercialization of its broad pipeline of RNAi therapeutic candidates.

In April, the company and Regeneron Pharmaceuticals (NASDAQ:REGN) extended their collaboration agreement. Both companies will work together to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and the central nervous system (CNS), in addition to a select number of targets expressed in the liver. The companies plan to advance programs directed to 30 targets. Other candidates also might be introduced into clinical development during the initial five-year discovery period, which may extend.

With only one approved product in its portfolio, Alnylam derives a substantial amount of revenues from partnerships with companies like Sanofi (NASDAQ:SNY) , Takeda and Monsanto (NYSE:MON), among others. Therefore, the company is heavily dependent on its partnerships for its operations and pipeline development activities. Moreover, Alnylam is not the only company working on the development of RNAi-based therapeutics. Companies like Ionis, Sarepta Therapeutics and Roche Innovation Center are involved in the development of RNA-based drugs.

Alnylam currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>



Sanofi (SNY): Free Stock Analysis Report

Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

The Medicines Company (MDCO): Free Stock Analysis Report

Original post
Alnylam Focuses On Pipeline Development Amid Competition
 

Related Articles

Alnylam Focuses On Pipeline Development Amid Competition

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email